688098 申联生物
午间休市 07-23 11:28:26
资讯
新帖
简况
股市必读：申联生物（688098）7月20日董秘有最新回复
证券之星 · 07-21 02:07
股市必读：申联生物（688098）7月20日董秘有最新回复
申联生物最新公告：获批含南非1型口蹄疫疫苗产品批准文号
证券之星 · 07-20 20:49
申联生物最新公告：获批含南非1型口蹄疫疫苗产品批准文号
申联生物：在研创新药具备差异化竞争优势
证券之星 · 07-20 16:48
申联生物：在研创新药具备差异化竞争优势
申联生物：公司始终以做大做强为目标
证券之星 · 07-20 16:48
申联生物：公司始终以做大做强为目标
7月17日申联生物跌7.28%，中信建投趋势领航两年持有混合A基金重仓该股
证券之星 · 07-17
7月17日申联生物跌7.28%，中信建投趋势领航两年持有混合A基金重仓该股
股市必读：申联生物（688098）7月15日董秘有最新回复
证券之星 · 07-16
股市必读：申联生物（688098）7月15日董秘有最新回复
股市必读：申联生物（688098）7月10日董秘有最新回复
证券之星 · 07-13
股市必读：申联生物（688098）7月10日董秘有最新回复
7月3日申联生物涨13.30%，中信建投趋势领航两年持有混合A基金重仓该股
证券之星 · 07-03
7月3日申联生物涨13.30%，中信建投趋势领航两年持有混合A基金重仓该股
股市必读：申联生物（688098）7月1日董秘有最新回复
证券之星 · 07-02
股市必读：申联生物（688098）7月1日董秘有最新回复
申联生物：UB-221国内II期临床试验已顺利完成145例受试者入组及出组
证券之星 · 07-01
申联生物：UB-221国内II期临床试验已顺利完成145例受试者入组及出组
每周股票复盘：申联生物（688098）获猪口蹄疫疫苗批文
证券之星 · 06-28
每周股票复盘：申联生物（688098）获猪口蹄疫疫苗批文
股市必读：申联生物（688098）6月15日董秘有最新回复
证券之星 · 06-16
股市必读：申联生物（688098）6月15日董秘有最新回复
申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式
证券之星 · 06-15
申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式
6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股
证券之星 · 06-10
6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股
申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组
证券之星 · 06-08
申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组
申联生物：公司生产经营活动一切正常
证券之星 · 06-03
申联生物：公司生产经营活动一切正常
每周股票复盘：申联生物（688098）设立2026年员工持股计划
证券之星 · 05-31
每周股票复盘：申联生物（688098）设立2026年员工持股计划
申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%
证券之星 · 05-27
申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%
每周股票复盘：申联生物（688098）推2026员工持股计划
证券之星 · 05-24
每周股票复盘：申联生物（688098）推2026员工持股计划
申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%
证券之星 · 05-20
申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%
公司概况
公司名称：
申联生物医药(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-28
主营业务：
申联生物医药(上海)股份有限公司的主营业务是动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗。
发行价格：
8.80
{"stockData":{"symbol":"688098","market":"SH","secType":"STK","nameCN":"申联生物","latestPrice":8.13,"timestamp":1784777306000,"preClose":8.27,"halted":0,"volume":995573,"delay":0,"changeRate":-0.0169,"floatShares":411000000,"shares":411000000,"eps":-0.0468,"marketStatus":"午间休市","change":-0.14,"latestTime":"07-23 11:28:26","open":8.18,"high":8.27,"low":8.11,"amount":8148400,"amplitude":0.0193,"askPrice":8.14,"askSize":11,"bidPrice":8.11,"bidSize":142,"shortable":0,"etf":0,"ttmEps":-0.0468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784782800000},"marketStatusCode":3,"adr":0,"adjPreClose":8.27,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784770200000,1784777400000],[1784782800000,1784790000000]],"highLimit":9.1,"lowLimit":7.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":410644000,"isCdr":false,"pbRate":2.45,"roa":"--","roe":"--","epsLYR":-0.05,"committee":0.529215,"marketValue":3339000000,"turnoverRate":0.0024,"status":1,"floatMarketCap":3339000000},"requestUrl":"/m/hq/s/688098/wiki","defaultTab":"wiki","newsList":[{"id":"2653248810","title":"股市必读：申联生物（688098）7月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653248810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653248810?lang=zh_cn&edition=full","pubTime":"2026-07-21 02:07","pubTimestamp":1784570829,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，申联生物报收于8.21元，下跌2.26%，换手率0.96%，成交量3.93万手，成交额3280.51万元。董秘最新回复投资者： 董秘你好！公司公告汇总关于获批含南非1型口蹄疫疫苗的兽药产品批准文号批件的自愿性披露公告申联生物子公司获批猪口蹄疫O型、南非1型二价灭活疫苗和牛羊口蹄疫O型、A型、南非1型三价灭活疫苗的兽药产品临时批准文号，有效期至2028年7月19日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100001593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215108","title":"申联生物最新公告：获批含南非1型口蹄疫疫苗产品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652215108?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:49","pubTimestamp":1784551757,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司获批猪口蹄疫O型、南非1型二价灭活疫苗和牛羊口蹄疫O型、A型、南非1型三价灭活疫苗的兽药产品临时批准文号，产品商品名分别为“泰优联”和“泰安联”。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000037225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652998332","title":"申联生物：在研创新药具备差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2652998332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652998332?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:48","pubTimestamp":1784537303,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物07月20日在投资者关系平台上答复投资者关心的问题。公司研发的几款创新药是不是没有市场竞争力？最近一个月创新药都是大涨的，其中很多翻倍的。而申联在其他创新药企业大涨时它反而下跌，其他创新药企业下跌时它暴跌申联生物回复：感谢您对公司的关注。二级市场股价波动受宏观经济环境、市场资金等多重因素影响。公司经营稳健，各项业务有序推进，在研创新药具备差异化竞争优势，目前临床进展符合既定预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652299886","title":"申联生物：公司始终以做大做强为目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2652299886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652299886?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:48","pubTimestamp":1784537293,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物(688098)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！公司领导有没有想着把公司做大做强？作为投资者损失惨重，从36元一路下跌，中间没有分红和转送股，而业绩一直没有改善。公司进入创新药领域也没有看到一个结果，真心失望申联生物回复：感谢您的关注。公司始终以做大做强为目标，经营层兢兢业业，各项业务和研发项目均在有序推进中。公司将继续聚焦主业，夯实研发，力争以扎实的经营成果回报股东。感谢您的理解与支持！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652055264","title":"7月17日申联生物跌7.28%，中信建投趋势领航两年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652055264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652055264?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:21","pubTimestamp":1784276484,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日申联生物跌7.28%，收盘报8.4元，换手率1.23%，成交量5.05万手，成交额4363.26万元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中信建投基金的中信建投趋势领航两年持有混合A。中信建投趋势领航两年持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098","BK0276","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651269493","title":"股市必读：申联生物（688098）7月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651269493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651269493?lang=zh_cn&edition=full","pubTime":"2026-07-16 03:38","pubTimestamp":1784144291,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，申联生物报收于9.39元，上涨4.57%，换手率1.41%，成交量5.79万手，成交额5424.58万元。董秘最新回复投资者： 董秘你好！近期资本市场创新药、医药类股票大多数都是上涨的，申联往往有大单往下砸。交易信息汇总资金流向7月15日主力资金净流出96.67万元，占总成交额0.0%；游资资金净流入23.0万元；散户资金净流入73.67万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600004209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651916692","title":"股市必读：申联生物（688098）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651916692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651916692?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:44","pubTimestamp":1783881851,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，申联生物报收于9.15元，下跌0.54%，换手率1.2%，成交量4.92万手，成交额4539.19万元。董秘最新回复投资者： 董秘你好！感谢你每次及时回复！就不要拖延时间了，艾滋病患者日夜等待中董秘： 感谢您对公司的关注和建议。交易信息汇总资金流向7月10日主力资金净流出161.31万元，占总成交额0.0%；游资资金净流入321.45万元，占总成交额0.0%；散户资金净流出160.14万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654057","title":"7月3日申联生物涨13.30%，中信建投趋势领航两年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648654057?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:33","pubTimestamp":1783067629,"startTime":"0","endTime":"0","summary":"证券之星消息，7月3日申联生物涨13.30%，收盘报9.88元，换手率4.08%，成交量16.77万手，成交额1.61亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中信建投基金的中信建投趋势领航两年持有混合A。中信建投趋势领航两年持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300029877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","601066","BK0276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648360526","title":"股市必读：申联生物（688098）7月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648360526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648360526?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:15","pubTimestamp":1782936912,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，申联生物报收于8.8元，上涨2.44%，换手率1.04%，成交量4.29万手，成交额3725.78万元。董秘最新回复投资者： 请问创新药u221进展如何？公司将持续加快创新药的研发进度，积极推进各项目临床与申报工作，力争早日实现产品落地。届时公司将根据创新药研发进展，及时履行信息披露义务。当日关注点交易信息汇总：7月1日主力资金净流出365.36万元，游资资金净流出182.79万元，散户资金净流入548.15万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200001961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648156655","title":"申联生物：UB-221国内II期临床试验已顺利完成145例受试者入组及出组","url":"https://stock-news.laohu8.com/highlight/detail?id=2648156655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648156655?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:12","pubTimestamp":1782893543,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物07月01日在投资者关系平台上答复投资者关心的问题。你们来点实际的吧申联生物回复：答：投资者您好，感谢您对公司的关注与建议。当前，UB-221在国内II期临床试验已顺利完成145例受试者入组及出组，预计今年三季度将读出关键数据，计划2026年底前提交Ⅲ期临床试验申请。公司将持续加快创新药的研发进度，积极推进各项目临床与申报工作，力争早日实现产品落地。届时公司将根据创新药研发进展，及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100029565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315745","title":"每周股票复盘：申联生物（688098）获猪口蹄疫疫苗批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315745","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646315745?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:49","pubTimestamp":1782589750,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，申联生物报收于8.62元，较上周的8.5元上涨1.41%。本周，申联生物6月24日盘中最高价报9.29元。申联生物当前最新总市值35.4亿元，在动物保健板块市值排名8/10，在两市A股市值排名3883/5206。此次获批将丰富公司猪口蹄疫疫苗产品线，提升市场竞争力，但实际收益受防疫政策、市场环境等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643478318","title":"股市必读：申联生物（688098）6月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2643478318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643478318?lang=zh_cn&edition=full","pubTime":"2026-06-16 03:24","pubTimestamp":1781551487,"startTime":"0","endTime":"0","summary":"截至2026年6月15日收盘，申联生物报收于8.53元，上涨2.28%，换手率0.89%，成交量3.67万手，成交额3121.87万元。董秘最新回复投资者： 最近美国拟对医药提出的两个法案《FDA法案》和巜COINS法案》对贵公司有无影响？公司将持续关注相关法案的进展，并积极研究其对行业的潜在影响。当日关注点交易信息汇总：6月15日主力资金净流入104.57万元，游资资金净流入19.4万元，散户资金净流出123.97万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600004387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276114","title":"申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643276114?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:33","pubTimestamp":1781512421,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月15日在投资者关系平台上答复投资者关心的问题。基于此，请问贵公司在2025年年度业绩说明会中，是否考虑采用视频直播并提供会后回放，以提升信息获取的便利性与透明度？公司2025年年度业绩说明会采用上证路演中心网络互动的方式，您可以通过上证路演中心官网查看本次说明会的召开情况及主要内容。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500019868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642499724","title":"6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642499724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642499724?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:38","pubTimestamp":1781080693,"startTime":"0","endTime":"0","summary":"证券之星消息，6月10日申联生物涨6.18%，收盘报8.08元，换手率1.48%，成交量6.07万手，成交额4862.71万元。重仓申联生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中信建投基金的中信建投趋势领航两年持有混合A。中信建投趋势领航两年持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601066","BK0276","688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483194","title":"申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641483194?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:06","pubTimestamp":1780913173,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月08日在投资者关系平台上答复投资者关心的问题。做点实事吧，不要只想着讲故事申联生物回复：投资者您好，感谢您对公司的关注与建议。关于股份回购事宜，公司已于2024年12月至2025年5月23日期间，累计回购股份3,417,373股，回购总金额达2,000万元。其中，UB-211已于2026年5月完成II期临床试验全部受试者出组。后续取得临床研究总结报告等关键进展时，公司将严格履行信息披露义务，敬请关注公司相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800025122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640908299","title":"申联生物：公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640908299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640908299?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:48","pubTimestamp":1780480102,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月03日在投资者关系平台上答复投资者关心的问题。公司生产经营活动一切正常，内部经营秩序良好，不存在应披露而未披露的重大信息。此外，股票价格受到宏观经济、二级市场波动等诸多因素影响，敬请投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604250","title":"每周股票复盘：申联生物（688098）设立2026年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604250","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604250?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:01","pubTimestamp":1780171297,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，申联生物报收于7.78元，较上周的8.23元下跌5.47%。本周，申联生物5月25日盘中最高价报8.41元。申联生物当前最新总市值31.95亿元，在动物保健板块市值排名10/10，在两市A股市值排名4358/5207。本周关注点公司公告汇总：申联生物设立2026年员工持股计划，选举产生管理委员会成员。所有议案均获全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638460689","title":"申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638460689","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638460689?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:43","pubTimestamp":1779892994,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，申联生物报收于7.98元，较前一交易日下跌0.99%，最新总市值为32.77亿元。该股当日开盘8.07元，最高8.12元，最低7.91元，成交额达1627.36万元，换手率为0.5%。近日，申联生物披露《2026年员工持股计划第一次持有人会议决议公告》。公告显示，公司召开2026年员工持股计划第一次持有人会议，审议通过设立员工持股计划管理委员会，并选举于海霞、王蕾、王锐为委员，其中王锐任主任。所有议案均获全票通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337615","title":"每周股票复盘：申联生物（688098）推2026员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637337615?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:02","pubTimestamp":1779570136,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，申联生物报收于8.23元，较上周的8.49元下跌3.06%。本周关注点公司公告汇总：申联生物发布2026年员工持股计划，拟参与人数不超过65人。公司公告汇总：2026年员工持股计划考核目标为取得4项兽 药批准文号并实现4款新疫苗上市。申联生物发布2026年员工持股计划，拟参与人数不超过65人，资金来源为员工合法薪酬及自筹资金，股份来源为公司回购专用账户中不超过341.7373万股股份，约占总股本0.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636251918","title":"申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636251918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636251918?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:39","pubTimestamp":1779287953,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，申联生物报收于8.37元，较前一交易日下跌1.88%，最新总市值为34.37亿元。该股当日开盘8.47元，最高8.56元，最低8.28元，成交额达1924.95万元，换手率为0.56%。近日，申联生物医药(上海)股份有限公司披露《2025年年度股东会决议公告》。中小投资者对部分议案单独计票，相关关联股东已回避表决。上海市锦天城律师事务所对本次会议出具法律意见书，认为会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784780603220,"stockEarnings":[{"period":"1week","weight":-0.1193},{"period":"1month","weight":-0.0428},{"period":"3month","weight":-0.0339},{"period":"6month","weight":-0.1705},{"period":"1year","weight":0.2743},{"period":"ytd","weight":-0.0687}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0711},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0651},{"period":"1year","weight":0.0796},{"period":"ytd","weight":-0.0257}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"申联生物医药(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10068人(较上一季度减少7.88%)","perCapita":"40787股","listingDate":"2019-10-28","address":"上海市闵行区江川东路48号","registeredCapital":"41064万元","survey":" 申联生物医药(上海)股份有限公司的主营业务是动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"申联生物,688098,申联生物股票,申联生物股票老虎,申联生物股票老虎国际,申联生物行情,申联生物股票行情,申联生物股价,申联生物股市,申联生物股票价格,申联生物股票交易,申联生物股票购买,申联生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}